According to these studies, CD80-Fc may even be effective in treating anti-PD-1 or anti-CTLA-4 -resistant patients and in our study its combination with 4-1BBL-Fc (Figs 3 and 5) enhanced immune response against tumor cells. The gene discussed is PDCD1; the disease is neoplasm.